National Cancer Institute renews Cancer Center designation for Huntsman Cancer Institute

December 30, 2010

Salt Lake City, December 30, 2010--Officials at Huntsman Cancer Institute (HCI) at the University of Utah announced that the National Cancer Institute (NCI) has renewed its prestigious designation as a Cancer Center. The NCI designation recognizes the outstanding cancer research conducted at HCI, which holds the only such designation in the five-state Intermountain West and is the only NCI-designated Cancer Center within 500 miles of Salt Lake City.

"I am tremendously proud of the physicians, scientists, and administrative staff at HCI that have made this renewal possible," says Jon M. Huntsman, HCI's founding benefactor. "This highly prestigious designation includes only the nation's elite cancer institutions, those that demonstrate exceptional ability to conduct cancer research. As part of the renewal process, HCI was evaluated by a team of 30 national cancer experts during a competitive grant review and site visit. HCI received the strongest rating in its history and was ranked in the "High Impact" category."

The NCI designation recognizes the pivotal role of research in the development of improvements in cancer detection, diagnosis, treatment, and prevention and is reserved only for Cancer Centers that achieve the highest standards of excellence in cancer research. HCI received the prestigious NCI designation following a rigorous scientific review and evaluation of performance and expertise in several essential elements, including the quality and impact of the Center's cancer research, the availability of state-of-the art research and patient care facilities, experienced scientific leadership, and the level of collaboration and translation of science to innovative cancer care.

HCI's research excellence has been made possible by generous support of the Huntsman family and the Huntsman Cancer Foundation which supports HCI's research mission via philanthropic contributions. An outstanding ten-member External Advisory Board provides planning and evaluation direction to HCI, and includes such luminaries as Dr. Edward Benz, President of the Dana-Farber Cancer Institute of Harvard University and Nobel Laureate, Dr. Elizabeth Blackburn of the University of California at San Francisco.

"The highly laudatory review of HCI's programs by thought leaders in cancer research affirms the innovation and impact of our cancer research efforts. NCI designation brings financial resources to support further development of our research infrastructure, ensuring that we have cutting-edge technologies and expertise," says Mary Beckerle, Ph.D., HCI's executive director. "The national recognition of our accomplishments and potential for future excellence allows us to attract top faculty and additional grant support for cancer research."

HCI currently has 135 faculty researchers and more than $60 million in extramural grants. Considered a world leader in the study of cancer genetics, HCI researchers have earned international recognition for their work to identify the gene mutations responsible for colon cancer, breast and ovarian cancer, melanoma, neurofibromatosis, and, most recently, hereditary paraganglioma. A strategic focus of HCI is to leverage genetic understanding of cancer to personalize cancer risk assessment, diagnosis, and treatment.

"I have had the privilege of visiting HCI on many occasions since it was established," says Utah Sen. Orrin Hatch. "The recent NCI review confirms HCI's status as an elite cancer research center, its commitment to excellence, and the significant impact it has had in the cancer research field. The research performed there provides real hope and lifesaving results for cancer patients and their families."
-end-
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies in the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. One of the responsibilities Congress has delegated to the agency is to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

University of Utah Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.